US20110162644A1 - Methods and apparatus for supplying clean breathable gas - Google Patents

Methods and apparatus for supplying clean breathable gas Download PDF

Info

Publication number
US20110162644A1
US20110162644A1 US13/030,488 US201113030488A US2011162644A1 US 20110162644 A1 US20110162644 A1 US 20110162644A1 US 201113030488 A US201113030488 A US 201113030488A US 2011162644 A1 US2011162644 A1 US 2011162644A1
Authority
US
United States
Prior art keywords
patient
flow
blower
mask
filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/030,488
Inventor
Anthony John Ujhazy
Jonathan Caldwell Wright
Joanne Elizabeth Drew
Michael Berthon-Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resmed Pty Ltd
Original Assignee
Resmed Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resmed Pty Ltd filed Critical Resmed Pty Ltd
Priority to US13/030,488 priority Critical patent/US20110162644A1/en
Assigned to RESMED LIMITED reassignment RESMED LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UJHAZY, ANTHONY JOHN, BERTHON-JONES, MICHAEL, DREW, JOANNE ELIZABETH, WRIGHT, JONATHAN CALDWELL
Publication of US20110162644A1 publication Critical patent/US20110162644A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06Respiratory or anaesthetic masks
    • A61M16/0605Means for improving the adaptation of the mask to the patient
    • A61M16/0633Means for improving the adaptation of the mask to the patient with forehead support
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • A61M16/0066Blowers or centrifugal pumps
    • A61M16/0069Blowers or centrifugal pumps the speed thereof being controlled by respiratory parameters, e.g. by inhalation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/021Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
    • A61M16/022Control means therefor
    • A61M16/024Control means therefor including calculation means, e.g. using a processor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/105Filters
    • A61M16/106Filters in a path
    • A61M16/107Filters in a path in the inspiratory path
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0051Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06Respiratory or anaesthetic masks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06Respiratory or anaesthetic masks
    • A61M16/0605Means for improving the adaptation of the mask to the patient
    • A61M16/0611Means for improving the adaptation of the mask to the patient with a gusset portion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0015Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
    • A61M2016/0018Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
    • A61M2016/0021Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0039Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/70General characteristics of the apparatus with testing or calibration facilities
    • A61M2205/707Testing of filters for clogging

Definitions

  • the invention relates to a method and apparatus for providing a supply of clean breathable gas particularly during sleep. More specifically, the invention relates to devices that may be used to detect, diagnose, treat, manage and/or prevent asthma symptoms in patients.
  • a known acute therapy for asthma is oral delivery of a broncho-dilator such as albuterol (also known as salbutamol).
  • a broncho-dilator such as albuterol (also known as salbutamol).
  • albuterol also known as salbutamol
  • VentolinTM manufactured by SmithKline Beecham.
  • a vasodilator such as a therapeutically effective amount of nitric oxide as disclosed in U.S. Pat. No. 5,873,359.
  • the invention features an apparatus for providing a supply of clean breathable gas that is designed for those who suffer from asthma.
  • the apparatus includes a blower with an allergen filter, such as a HEPA filter, an air delivery conduit and a patient interface, and may be conveniently designed for portable or outpatient use.
  • the blower provides air to the patient interface at a preferred range of pressure from 1 to 4 cm H 2 O.
  • the blower includes a flow meter for monitoring the flow of air to and from the patient.
  • the apparatus may include a controller such as a microprocessor for analyzing the flow signal to determine asthma-related symptoms, for example, by calculating an index of roundness or flatness of the flow curve, or both, which may be indicative of the bronchial hyperactivity that characterizes asthma or partial obstruction of the airways.
  • the device also monitors the tidal volume of the patient's respiration.
  • the device may include an alarm for alerting the patient or a care-giver that the person using the device may be suffering an asthma attack.
  • the device includes apparatus for delivering to the patient a dose of a therapeutic drug or other therapeutically-effective substance.
  • the delivery of oxygen or other therapeutic substance is synchronized with the inspiratory phase of the breathing cycle.
  • FIG. 1 shows a prior art device for air filtration
  • FIG. 2 shows one embodiment of an apparatus according to the invention
  • FIG. 3 depicts a porous mask suitable for use with the invention
  • FIG. 4 illustrates another patient interface having a porous portion for use with the invention
  • FIG. 5 depicts another patient interface designed in accordance with the goals of the invention.
  • FIG. 6 illustrates the positioning of the mask of FIG. 5 on a user.
  • the asthma treatment/prevention apparatus of the invention includes a blower or other similar device to generate a flow of breathable gas under pressure to a user.
  • the blower 2 supplies breathable gas, such as air, to a patient interface 4 , e.g. a mask, via an air delivery conduit 6 as shown in FIG. 2 .
  • breathable gas such as air
  • An example of a suitable blower can be either the RESMED S6TM and S7TM blowers (ResMed Limited). Another suitable blower is found in the AUTOSET TTM and AUTOSET SPIRITTM devices (ResMed Limited).
  • the blower consists of an electric motor 2 A connected to an impeller 2 B, the impeller being housed in a suitable volute 2 C, for example as described in PCT/AU99/00444.
  • the blower 2 is designed to have a rising fan curve. This means that as the flow increases, the pressure delivered by the blower increases so as the patient progresses through each cycle of inhalation and exhalation, the mask pressure remains relatively constant.
  • the blower may be process controlled by a controller to implement such a regulation of the mask pressure.
  • the blower motor 2 A is a mains voltage AC motor.
  • a power transformer would not be required, reducing the cost of the device.
  • the use of such a motor would dictate a larger impeller than would be the case where the blower uses a lower than mains voltage AC motor or a DC motor.
  • a multistage impeller could be used with the AC motor.
  • the flow rate must exceed the minimum requirements of breathing to ensure adequate CO 2 washout from the patient interface 4 .
  • a typical normal patient might have a tidal volume of 0.5 L and a breathing frequency of 10 to 15 breaths per minute.
  • the apparatus must deliver in excess of approximately 10 L/min.
  • the flow rate may be several multiples of the minimum breathing requirements.
  • the desired CO 2 washout flow may dictate a higher flow.
  • the apparatus is designed to have a minimum washout flow of 25 litres/min.
  • the blower 2 of the apparatus in conjunction with the patient interface 4 has the capacity to deliver sufficient flow in an approximate pressure range of 1 cm H 2 O to 4 cm H 2 O above ambient pressure.
  • the device may also vary the pressure delivered in the mask from inspiration to expiration (lower for expiration) to assist with the ventilation.
  • a suitable device for this purpose is the VPAPTM positive pressure nasal ventilation device by ResMed Limited.
  • the expiratory pressure i.e. the mask pressure during expiration
  • the inspiration pressure i.e. the mask pressure during inspiration
  • the automatic ventilatory control may be applied to expiration pressure by adopting the techniques taught in U.S. Pat. No. 5,704,345.
  • the breathable gas that is supplied by the apparatus is substantially free of allergen particles or other asthma symptom-inducing particulates or pollutants.
  • the capacity for removing asthma symptom-inducing particulates is provided.
  • this capacity is provided to function in conjunction with the blower 2 or it may be externally adapted thereto.
  • the blower inlet 2 D may include an air cleaning device 10 or filter designed to remove allergens from the ambient air.
  • the air cleaning device 10 or filter may also be designed to remove other air pollutants or particulates.
  • Known air cleaning devices include mechanical filters, electronic filters, hybrid filters (mechanical/electrostatic filters), gas phase filters or ozone generators.
  • a preferred example of a suitable filter for use in the invention is a HEPA filter, alone or in combination with activated carbon. It is generally accepted that a HEPA filter will remove 99.97 percent of airborne particles having a size of 0.3 microns or larger.
  • the air delivery conduit 6 may be a gas delivery tubing as commonly used with CPAP devices having a cross-sectional diameter of approximately 22 cm.
  • a gas delivery tube of at least 22 cm cross-sectional diameter is required to minimize mask pressure swings to a clinically acceptable extent.
  • the pressure swings occur as the patient inhales and exhales.
  • An embodiment of the present invention may operate within a mask pressure range that is typically less than that used in conventional CPAP for the treatment of obstructive sleep apnea.
  • the pressure range may be between 1.75 cm H 2 O and 2.5 cm H 2 O. In view of this lower mask pressure range used in an embodiment of the present invention it is less susceptible to clinically significant mask pressure swings.
  • any pressure drop is not of significance so long as the final pressure near the wearer's nose and/or mouth remains slightly above the ambient pressure.
  • the tubing used may have a smaller cross-sectional diameter than the tubing used for conventional CPAP therapy and therefore be less bulky. When used in this invention the less bulky tubing will not be unacceptable solely as a consequence of it introducing pressure swings through the breathing cycle.
  • the tubing used must be capable of supplying to the mask gas flow sufficient to meet the patient's breathing requirements as well as washing out excess CO 2 irrespective of whether it induces pressure swings. The less bulky tubing should facilitate user comfort and ultimately patient compliance.
  • the apparatus is supplied with a patient interface 4 .
  • a purpose of the interface 4 is to substantially limit the breathable air of the patient to the gas that is supplied through the apparatus and thereby minimize patient intake of air from alternative sources, such as directly from the ambient environment, which may potentially contain asthma symptom-inducing particulates.
  • the patient interface may be a nasal mask, for example, the MIRAGETM nasal mask (ResMed Ltd).
  • the MIRAGETM full-face mask which covers mouth and nose openings of the patient, may be used as a patient interface.
  • the mask is held in position on the head by headgear constructed from hypoallergenic material.
  • a suitable headgear is the MIRAGETM headgear (ResMed Ltd).
  • the patient mask is designed to permit a delivery of breathable gas at a pressure of approximately 1 cm H 2 0 to 4 cm H 2 O above ambient pressure.
  • the mask may be of a different design to a mask for treating OSA.
  • the sealing membrane 24 for a regular CPAP mask is constructed from silicone rubber of 40 durometer hardness, for example, 595 HC manufactured by DOW and may be 0.3 mm to 0.5 mm thick.
  • the thickness may be reduced to 0.1 mm to 0.3 mm. The thinner membrane may lead to greater patient comfort.
  • the mask includes a porous rigid frame 26 to allow CO 2 washout.
  • the mask is designed to be totally open when the blower is off, acting as an anti-asphyxia valve. This may be accomplished by constructing the mask with a rigid open frame connected to the air delivery conduit, via, in one form, a swivel or ball and socket joint.
  • the mask also contains a membrane with a generally triangular patient-contacting-portion and a bellows shaped non-patient-contacting portion. When the mask is operating under pressure, the flow of air causes the bellows to expand and seal with the air delivery conduit. When the mask is not operating under pressure, the bellows retract, leaving the patient free to breath ambient air.
  • Other suitable masks with anti-asphyxia valves are disclosed in International Publication no. WO/0038772, U.S. Pat. Nos. 5,896,857 and 6,189,532. The disclosures of which are hereby incorporated by reference.
  • the mask in another form of the invention, includes a lockable swivel or ball and socket joint which enables the air delivery tube to be moved about in a number of different positions, but locked into one of these when desired.
  • FIG. 4 depicts a polycarbonate mask appropriate for use with the invention.
  • the mask has an addition of two extra vents (only one shown) each consisting of a stainless steel 316 disk 28 secured to the mask shell by way of a silicone grommet which holds the disk in a planer relationship to the mask shell and covers an orifice punched in the mask shell.
  • Each disk is circular, 22 mm diameter, 0.5 mm thick and has 97 circular perforations between its planer sides each perforation being circular 1.2 mm ⁇ 1.8 pitch.
  • the perforations may be sized to insure adequate CO 2 washout and help to prevent asphyxia in the event of blower failure and/or limit the permissible pressure level in the mask.
  • the mask can provide to the patient a pressure range between 1.75 cm H 2 0 and 2.5 cm H 2 O.
  • the mask may also be used in trials and studies in relation to other ventilatory assist techniques. For example to compare the effectiveness of a new therapy in a blind trial fashion against minimal or no therapy. In such applications it is worn by the subject in association with the requisite gas conduit and flow generator. In such a configuration the mask will not deliver to the subject a-pressure above its designated top pressure notwithstanding that the flow generator control circuit instructs the flow generator to operate at a level which would deliver a higher pressure had a regular mask been used.
  • a mask consisting of a shield with a partial cushion designed to seal on the nose may be utilized.
  • a mask is positioned on the nose below the nose bridge, so as to avoid that sensitive part of the patient's anatomy.
  • An illustration of such a mask in accordance with this embodiment can be seen in FIG. 5 and FIG. 6 .
  • the sealing membrane 24 is positioned with the intent of preventing gas flow into the user's eyes.
  • the lower part of the mask is open (i.e. is not sealed) and so directs gas downwards over the nares and preferably the mouth so as to provide a ‘curtain’ of breathable gas.
  • This open lower part 30 of the mask provides washout of exhaled carbon dioxide.
  • This interface is designed to be small and light and of minimal impact on the wearer.
  • the intent is to provide a micro atmosphere with a flow of filtered breathable gas that excludes the ambient air to an extent that the patient preferentially breathes the filtered air.
  • the apparatus of the invention is designed with a controller 12 .
  • the controller 12 may include a microprocessor with a medium for programmed instructions or other processor or electronic circuitry to direct the functioning of the apparatus.
  • the controller 12 accepts signals from a flow meter 18 , for example, a differential pressure transducer.
  • the controller may also include pressure transducers for sensing pressure levels in the mask.
  • the controller monitors the output from the flow meter, as well as the current to the motor and the number of revolutions per minute of the motor.
  • the controller also controls the display of information on the exterior of the apparatus and is responsive to switches mounted on the exterior.
  • the controller 12 may be designed to direct the delivery of therapeutic substances, such as a therapeutic gas, drugs and/or supplemental oxygen to the patient interface as further described herein.
  • the device may include a reservoir and pump, or for substances stored under pressure, such as oxygen, a reservoir without a pump.
  • An example of a suitable device for delivery of a therapeutic substance, drug or, oxygen, is described in U.S. Pat. No. 6,029,660 (also disclosed in AU Patent 719758 and PCT AU97/00846). The disclosure of U.S. Pat. No. 6,029,660 is hereby incorporated by reference. Such an apparatus is relatively small compared with the prior art.
  • the therapeutic substance delivery devices 14 A, 14 B administer treatment to the patient under the control of the controller 12 which may control delivery based upon a predetermined schedule and/or the current condition of the patient.
  • the therapeutic substance, drug or supplemental oxygen may be administered directly in the patient interface 4 or alternatively in the blower 2 .
  • the flow meter 18 measures flow by a differential pressure transducer. Flow of filtered air from the blower passes through a bundle of small tubes 20 aligned in parallel with the flow from the blower. The pressure difference across the bundle varies according to Bernoulli's law. Hence a measure of the flow of air to the mask (raw flow signal) may be calculated.
  • the patient interface 4 includes a deliberate leak through a vent 22 and also typically there is an unintentional leak around the edges of the seal and through other air delivery conduit joints. Since the volumes of air that the patient inhales and exhales over several breaths is approximately equal, an average flow signal over several breaths will provide a measure of the leakage of air from the system.
  • a low-pass filtered air signal where the filter constant is longer than several breaths, will provide another estimate of the leakage of air from the system.
  • leak flow may be determined according to PCT/AU97/00517. Having determined the long-term average (or low-pass filtered) leak flow, a measure of the instantaneous respiratory airflow may be obtained by subtracting the long-term average signal from the raw flow signal.
  • the respiratory flow signal is a periodic waveform. By convention, inspiration is a positive flow and expiration is a negative flow. Hence it is possible to estimate the transition points between inspiration and expiration from the zero crossing points.
  • this enables the apparatus to synchronize delivery of therapeutic substances, drugs or supplemental oxygen to the inspiratory phase of the breathing cycle and reduce waste of the substance, drug or oxygen. If administered in the blower, then the delivery must be synchronised to account for any propagation delay through the air delivery conduit.
  • the apparatus may be programmed as an asthma attack or asthma-related symptom detector to trigger treatment or to provide a warning of the occurrence of such an attack or such symptoms.
  • the microprocessor in the device reads the flow signal and determines on a breath-by-breath basis, an index of the roundness or alternatively flatness of the inspiratory portion of the flow time curve.
  • the inspiratory portion of a normal breath waveform has a round shape. If the inspiratory portion of the waveform is flattened or shaped like a square-wave, then it is indicative of partial obstruction of the airway, for example, constriction or narrowing of the bronchus or other asthma-related narrowing of the airways of the lung.
  • One form of flatness index is the RMS deviation of the inspiratory flow curve from a square wave of the same length and area.
  • One form of roundness index is the RMS deviation from a sine wave of the same length and area.
  • the inspiratory flow curve may be scaled to have unit length and area and compared to square and sine waves of unit dimensions. Examples of the formulae for calculating such indices are disclosed in U.S. Pat. No. 5,704,345 which is hereby incorporated by reference.
  • an inspiratory waveform which closely resembles a square wave will have a small RMS deviation from that waveform and hence have a small flatness index. Conversely, it will have a larger RMS deviation from the sine wave and have a larger roundness index.
  • An inspiratory waveform which closely resembles a sine wave will have a small RMS deviation from that waveform and hence a small roundness index. Conversely, it will have a larger RMS deviation from a square wave and have a larger flatness index.
  • the device provides an alarm and logs the information when the roundness and flatness indices indicate the presence of partial obstruction when compared with predetermined thresholds. In this way the device can determine physiologic changes in the user's breathing patterns and indicate the onset of changes consistent with the onset or occurrence of an asthma attack.
  • the apparatus monitors the shape of the expiratory portion of the flow time curve.
  • Abnormally shaped expiratory flow time curves are taken to be indications of the presence of a partial obstruction and the device responds by issuing a warning, logging the event and indicating the possible need for therapy. For example, this may be accomplished by analyzing an expiratory waveform to determine a flatness or roundness index.
  • the delivery of therapeutic agents or treatments is monitored and recorded together with time and date stamp and other clinically relevant data including user blood oxygen concentration, environmental conditions such as current allergen load and ambient humidity.
  • This data is then processed and made available, say to the clinician, for review.
  • Reported statistics may include frequency and time distribution of airway events (such as deviation from the desired inspiratory or expiratory flow curve) and therapy doses. This data is used for the management of the patient in accessing their response to therapies and as an aid in determining future therapeutic agent dosing.
  • the device may be programmed to respond by delivery of a predetermined therapeutic response (say by delivery of a therapeutic agent in a predetermined titration regime or ventilatory assistance) and thereby manage the patient's condition in a timely manner.
  • a predetermined therapeutic response say by delivery of a therapeutic agent in a predetermined titration regime or ventilatory assistance
  • the device can be programmed to act in a proactive manner by recognizing the onset of conditions that have previously resulted in an airway event and deliver the therapeutic response to stabilize the patient prior to the patient having an airway event that warrants a more significant therapeutic response.
  • the effectiveness of a therapeutics response may be studied by programming the device to only provide a therapeutic response to an identified set of conditions (e.g. patient physiological state or atmospheric conditions or both) on some occasions and not on others. By examination of the monitored data it is possible to determine the effectiveness of the therapeutic response.
  • an identified set of conditions e.g. patient physiological state or atmospheric conditions or both
  • a data management system will build and regularly update templates of patient responses to conditions and therapeutic responses in order to characterize patient responses and thereby provide patient specific data to an expert system decision tree.
  • the decision tree may be used to determine future therapy strategies.
  • the capacity to eliminate the filtered air reaching the patient so that unfiltered air reaches the patient may be provided. This capacity allows for the ability to identify correlations between environmental contaminates and airway events and therapeutic responses.
  • the apparatus is provided with an attachment for spirometry in the mask.
  • the nose is blocked and the patient is instructed to take a deep breath and blow into the tubing in accordance with known techniques for measuring respiratory function.
  • the device measures the flow and pressure and logs the peak flow and the total volume exhaled during the first 1 second of exhalation. The data from these measurements are available for both the patient and physician.
  • the apparatus automatically detects the efficiency or status of the air cleaning device.
  • the controller is configured to monitor the impedance of an air filter by monitoring the power required to deliver a certain pressure and flow or some other measurable function of the blower such as its velocity or r.p.m. As the filter becomes blocked its impedance increases. When the filter impedance has reached a predetermined threshold, a warning is given as an alarm or message display to say that the filter should be replaced.
  • the apparatus monitors the number of hours of use of the device since some filters ought to be replaced after a fixed number of hours of use. Suitable techniques and algorithms for such monitoring are described in international patent application No. PCT/AU99/0972 (also bearing international publication No. WO00/27457).
  • the apparatus delivers a higher pressure of air to the patient during the inspiratory portion of the patient's breathing cycle.
  • the higher inspiratory pressure is less than 10 cm H 2 O.
  • the apparatus is delivering a therapeutic drug, for example by pumping the drug at pressure from a reservoir, the pressure of drug delivery is controlled to be higher than the mask pressure.
  • the apparatus automatically increases the pressure of the drug delivery to be higher than the mask pressure by a predetermined offset.

Abstract

The invention features methods and apparatus for the treatment of asthma patients. A controlled supply of breathable air delivered to a patient interface or mask (4) is controlled for patient comfort to maintain a steady pressure level in a range 2 to 4 cm H2O to accommodate patient respiration. The breathable air is cleaned by a high efficiency particulate arresting filter (10) to remove allergens from the air supply. The apparatus may be programmed to automatically detect asthma-related symptoms such as an asthma attack by analyzing the respiratory flow of the patient. In response to the detection of such an attack, the apparatus may provide an audible warning or if configured with a treatment delivery module (14A, 14B), the device may administer a therapeutically effective dose of a drug or substance, for example, a broncho-dilator, to alleviate the patient's breathing difficulty. Preferred mask designs allow for proper CO2 washout to accommodate the low pressures supplied to the mask and prevent asphyxia.

Description

  • This application claims the priority filing date of Australian provisional patent application serial number PR3154 filed on Feb. 16, 2001.
  • FIELD OF THE INVENTION
  • The invention relates to a method and apparatus for providing a supply of clean breathable gas particularly during sleep. More specifically, the invention relates to devices that may be used to detect, diagnose, treat, manage and/or prevent asthma symptoms in patients.
  • BACKGROUND OF THE INVENTION
  • The presence of airborne particles such as pollen, fungal spores and dust mites in bedrooms is associated with respiratory diseases such as asthma. The United States National Institutes of Health (NIH) recommends removing such things as pets, rugs, carpets and curtains to reduce the presence of allergens in the bedroom (NIEHS Fact Sheet #9, ASTHMA, 7/97). A known solution is to place an air filter in the bedroom such as the Austin Healthmate which includes HEPA (High Efficiency Particulate Arresting) filters and activated carbon. HEPA technology is described in U.S. Pat. Nos. 4,629,482, 4,685,944 and 6,289,974. Such air filters are provided as free-standing units as shown in FIG. 1. These devices are said to clean the air in a typical sized bedroom in 15 to 30 minutes. Known problems with such devices include that they can be too noisy to run continuously while a person is attempting to sleep in the same room, as well as the possibility of the room becoming recontaminated every time that the door, windows or ventilation ducts are opened.
  • A known acute therapy for asthma is oral delivery of a broncho-dilator such as albuterol (also known as salbutamol). One form of this drug is Ventolin™ manufactured by SmithKline Beecham. Another example of a therapy used for the treatment of asthma is the delivery of a vasodilator such as a therapeutically effective amount of nitric oxide as disclosed in U.S. Pat. No. 5,873,359.
  • SUMMARY OF THE INVENTION
  • The invention features an apparatus for providing a supply of clean breathable gas that is designed for those who suffer from asthma. The apparatus includes a blower with an allergen filter, such as a HEPA filter, an air delivery conduit and a patient interface, and may be conveniently designed for portable or outpatient use. The blower provides air to the patient interface at a preferred range of pressure from 1 to 4 cm H2O. The blower includes a flow meter for monitoring the flow of air to and from the patient. The apparatus may include a controller such as a microprocessor for analyzing the flow signal to determine asthma-related symptoms, for example, by calculating an index of roundness or flatness of the flow curve, or both, which may be indicative of the bronchial hyperactivity that characterizes asthma or partial obstruction of the airways. The device also monitors the tidal volume of the patient's respiration. The device may include an alarm for alerting the patient or a care-giver that the person using the device may be suffering an asthma attack. In another embodiment, the device includes apparatus for delivering to the patient a dose of a therapeutic drug or other therapeutically-effective substance. In one form, the delivery of oxygen or other therapeutic substance is synchronized with the inspiratory phase of the breathing cycle.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a prior art device for air filtration;
  • FIG. 2 shows one embodiment of an apparatus according to the invention;
  • FIG. 3 depicts a porous mask suitable for use with the invention;
  • FIG. 4 illustrates another patient interface having a porous portion for use with the invention;
  • FIG. 5 depicts another patient interface designed in accordance with the goals of the invention;
  • FIG. 6 illustrates the positioning of the mask of FIG. 5 on a user.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As illustrated in FIG. 2., the asthma treatment/prevention apparatus of the invention includes a blower or other similar device to generate a flow of breathable gas under pressure to a user. The blower 2 supplies breathable gas, such as air, to a patient interface 4, e.g. a mask, via an air delivery conduit 6 as shown in FIG. 2. An example of a suitable blower can be either the RESMED S6™ and S7™ blowers (ResMed Limited). Another suitable blower is found in the AUTOSET T™ and AUTOSET SPIRIT™ devices (ResMed Limited). The blower consists of an electric motor 2A connected to an impeller 2B, the impeller being housed in a suitable volute 2C, for example as described in PCT/AU99/00444.
  • The blower 2 is designed to have a rising fan curve. This means that as the flow increases, the pressure delivered by the blower increases so as the patient progresses through each cycle of inhalation and exhalation, the mask pressure remains relatively constant. Alternatively, the blower may be process controlled by a controller to implement such a regulation of the mask pressure.
  • In one form of the invention, the blower motor 2A is a mains voltage AC motor. In this case a power transformer would not be required, reducing the cost of the device. The use of such a motor would dictate a larger impeller than would be the case where the blower uses a lower than mains voltage AC motor or a DC motor. Alternatively, a multistage impeller could be used with the AC motor.
  • The flow rate must exceed the minimum requirements of breathing to ensure adequate CO2 washout from the patient interface 4. A typical normal patient might have a tidal volume of 0.5 L and a breathing frequency of 10 to 15 breaths per minute. Hence the apparatus must deliver in excess of approximately 10 L/min. In order to allow for coughs or sighs, the flow rate may be several multiples of the minimum breathing requirements. However, the desired CO2 washout flow may dictate a higher flow. In one particularly preferred form, the apparatus is designed to have a minimum washout flow of 25 litres/min. The blower 2 of the apparatus in conjunction with the patient interface 4 has the capacity to deliver sufficient flow in an approximate pressure range of 1 cm H2O to 4 cm H2O above ambient pressure.
  • In accordance with the present invention the device may also vary the pressure delivered in the mask from inspiration to expiration (lower for expiration) to assist with the ventilation. A suitable device for this purpose is the VPAP™ positive pressure nasal ventilation device by ResMed Limited. Typically the expiratory pressure (i.e. the mask pressure during expiration) would be set to achieve adequate CO2 washout while the inspiration pressure (i.e. the mask pressure during inspiration) would be set to provide the requisite level of ventilatory assistance. In addition the automatic ventilatory control may be applied to expiration pressure by adopting the techniques taught in U.S. Pat. No. 5,704,345.
  • Such ventilatory control in the application of the automatic system will monitor and track the patient's ventilation and increase the level of ventilation support when low ventilation is detected based on a continuously updated template of medium term ventilation. Examples of techniques for monitoring ventilation and determining the appropriate ventilatory assist response can be found in PCT/AU97/00631 Berthon-Jones assignee ResMed Limited. Preferably, the breathable gas that is supplied by the apparatus is substantially free of allergen particles or other asthma symptom-inducing particulates or pollutants. Where ambient air is supplied through the blower 2, the capacity for removing asthma symptom-inducing particulates is provided. Preferably this capacity is provided to function in conjunction with the blower 2 or it may be externally adapted thereto. For example, the blower inlet 2D may include an air cleaning device 10 or filter designed to remove allergens from the ambient air. The air cleaning device 10 or filter may also be designed to remove other air pollutants or particulates. Known air cleaning devices include mechanical filters, electronic filters, hybrid filters (mechanical/electrostatic filters), gas phase filters or ozone generators. A preferred example of a suitable filter for use in the invention is a HEPA filter, alone or in combination with activated carbon. It is generally accepted that a HEPA filter will remove 99.97 percent of airborne particles having a size of 0.3 microns or larger.
  • The air delivery conduit 6 may be a gas delivery tubing as commonly used with CPAP devices having a cross-sectional diameter of approximately 22 cm. In conventional CPAP treatment it has become generally accepted that a gas delivery tube of at least 22 cm cross-sectional diameter is required to minimize mask pressure swings to a clinically acceptable extent. The pressure swings occur as the patient inhales and exhales. An embodiment of the present invention may operate within a mask pressure range that is typically less than that used in conventional CPAP for the treatment of obstructive sleep apnea. For example the pressure range may be between 1.75 cm H2O and 2.5 cm H2O. In view of this lower mask pressure range used in an embodiment of the present invention it is less susceptible to clinically significant mask pressure swings. In embodiments of the present invention any pressure drop is not of significance so long as the final pressure near the wearer's nose and/or mouth remains slightly above the ambient pressure. In another embodiment of the present invention the tubing used may have a smaller cross-sectional diameter than the tubing used for conventional CPAP therapy and therefore be less bulky. When used in this invention the less bulky tubing will not be unacceptable solely as a consequence of it introducing pressure swings through the breathing cycle. The tubing used must be capable of supplying to the mask gas flow sufficient to meet the patient's breathing requirements as well as washing out excess CO2 irrespective of whether it induces pressure swings. The less bulky tubing should facilitate user comfort and ultimately patient compliance.
  • As previously noted the apparatus is supplied with a patient interface 4. A purpose of the interface 4 is to substantially limit the breathable air of the patient to the gas that is supplied through the apparatus and thereby minimize patient intake of air from alternative sources, such as directly from the ambient environment, which may potentially contain asthma symptom-inducing particulates. The patient interface may be a nasal mask, for example, the MIRAGE™ nasal mask (ResMed Ltd). Alternatively the MIRAGE™ full-face mask, which covers mouth and nose openings of the patient, may be used as a patient interface. The mask is held in position on the head by headgear constructed from hypoallergenic material. A suitable headgear is the MIRAGE™ headgear (ResMed Ltd).
  • In one form, the patient mask is designed to permit a delivery of breathable gas at a pressure of approximately 1 cm H20 to 4 cm H2O above ambient pressure.
  • Because of the relatively low pressures in comparison to the application of nasal CPAP for treatment of OSA, the mask may be of a different design to a mask for treating OSA. Referring to FIG. 3, the sealing membrane 24 for a regular CPAP mask is constructed from silicone rubber of 40 durometer hardness, for example, 595 HC manufactured by DOW and may be 0.3 mm to 0.5 mm thick. However, because of the lower treatment pressures used in the present invention, in a mask for the present invention, the thickness may be reduced to 0.1 mm to 0.3 mm. The thinner membrane may lead to greater patient comfort.
  • In one form, the mask includes a porous rigid frame 26 to allow CO2 washout. In another form, the mask is designed to be totally open when the blower is off, acting as an anti-asphyxia valve. This may be accomplished by constructing the mask with a rigid open frame connected to the air delivery conduit, via, in one form, a swivel or ball and socket joint. The mask also contains a membrane with a generally triangular patient-contacting-portion and a bellows shaped non-patient-contacting portion. When the mask is operating under pressure, the flow of air causes the bellows to expand and seal with the air delivery conduit. When the mask is not operating under pressure, the bellows retract, leaving the patient free to breath ambient air. Other suitable masks with anti-asphyxia valves are disclosed in International Publication no. WO/0038772, U.S. Pat. Nos. 5,896,857 and 6,189,532. The disclosures of which are hereby incorporated by reference.
  • In another form of the invention, the mask includes a lockable swivel or ball and socket joint which enables the air delivery tube to be moved about in a number of different positions, but locked into one of these when desired.
  • FIG. 4 depicts a polycarbonate mask appropriate for use with the invention. The mask has an addition of two extra vents (only one shown) each consisting of a stainless steel 316 disk 28 secured to the mask shell by way of a silicone grommet which holds the disk in a planer relationship to the mask shell and covers an orifice punched in the mask shell. Each disk is circular, 22 mm diameter, 0.5 mm thick and has 97 circular perforations between its planer sides each perforation being circular 1.2 mm×1.8 pitch. The perforations may be sized to insure adequate CO2 washout and help to prevent asphyxia in the event of blower failure and/or limit the permissible pressure level in the mask. In this way, the mask can provide to the patient a pressure range between 1.75 cm H20 and 2.5 cm H2O. The mask may also be used in trials and studies in relation to other ventilatory assist techniques. For example to compare the effectiveness of a new therapy in a blind trial fashion against minimal or no therapy. In such applications it is worn by the subject in association with the requisite gas conduit and flow generator. In such a configuration the mask will not deliver to the subject a-pressure above its designated top pressure notwithstanding that the flow generator control circuit instructs the flow generator to operate at a level which would deliver a higher pressure had a regular mask been used.
  • In another form of the patient interface, a mask consisting of a shield with a partial cushion designed to seal on the nose may be utilized. Preferably it is positioned on the nose below the nose bridge, so as to avoid that sensitive part of the patient's anatomy. An illustration of such a mask in accordance with this embodiment can be seen in FIG. 5 and FIG. 6. The sealing membrane 24 is positioned with the intent of preventing gas flow into the user's eyes. The lower part of the mask is open (i.e. is not sealed) and so directs gas downwards over the nares and preferably the mouth so as to provide a ‘curtain’ of breathable gas. This open lower part 30 of the mask provides washout of exhaled carbon dioxide. It also serves an anti-asphyxia function by providing a safe breathing cavity when the blower is not functioning, thereby negating the need for additional anti-asphyxia components. This interface is designed to be small and light and of minimal impact on the wearer. The intent is to provide a micro atmosphere with a flow of filtered breathable gas that excludes the ambient air to an extent that the patient preferentially breathes the filtered air.
  • The apparatus of the invention is designed with a controller 12. The controller 12 may include a microprocessor with a medium for programmed instructions or other processor or electronic circuitry to direct the functioning of the apparatus. The controller 12 accepts signals from a flow meter 18, for example, a differential pressure transducer. The controller may also include pressure transducers for sensing pressure levels in the mask. The controller monitors the output from the flow meter, as well as the current to the motor and the number of revolutions per minute of the motor. The controller also controls the display of information on the exterior of the apparatus and is responsive to switches mounted on the exterior.
  • The controller 12 may be designed to direct the delivery of therapeutic substances, such as a therapeutic gas, drugs and/or supplemental oxygen to the patient interface as further described herein. The device may include a reservoir and pump, or for substances stored under pressure, such as oxygen, a reservoir without a pump. An example of a suitable device for delivery of a therapeutic substance, drug or, oxygen, is described in U.S. Pat. No. 6,029,660 (also disclosed in AU Patent 719758 and PCT AU97/00846). The disclosure of U.S. Pat. No. 6,029,660 is hereby incorporated by reference. Such an apparatus is relatively small compared with the prior art. The therapeutic substance delivery devices 14A, 14B administer treatment to the patient under the control of the controller 12 which may control delivery based upon a predetermined schedule and/or the current condition of the patient. The therapeutic substance, drug or supplemental oxygen may be administered directly in the patient interface 4 or alternatively in the blower 2.
  • In one embodiment, the flow meter 18 measures flow by a differential pressure transducer. Flow of filtered air from the blower passes through a bundle of small tubes 20 aligned in parallel with the flow from the blower. The pressure difference across the bundle varies according to Bernoulli's law. Hence a measure of the flow of air to the mask (raw flow signal) may be calculated. The patient interface 4 includes a deliberate leak through a vent 22 and also typically there is an unintentional leak around the edges of the seal and through other air delivery conduit joints. Since the volumes of air that the patient inhales and exhales over several breaths is approximately equal, an average flow signal over several breaths will provide a measure of the leakage of air from the system. Alternatively, a low-pass filtered air signal, where the filter constant is longer than several breaths, will provide another estimate of the leakage of air from the system. Alternatively, leak flow may be determined according to PCT/AU97/00517. Having determined the long-term average (or low-pass filtered) leak flow, a measure of the instantaneous respiratory airflow may be obtained by subtracting the long-term average signal from the raw flow signal. The respiratory flow signal is a periodic waveform. By convention, inspiration is a positive flow and expiration is a negative flow. Hence it is possible to estimate the transition points between inspiration and expiration from the zero crossing points. In turn this enables the apparatus to synchronize delivery of therapeutic substances, drugs or supplemental oxygen to the inspiratory phase of the breathing cycle and reduce waste of the substance, drug or oxygen. If administered in the blower, then the delivery must be synchronised to account for any propagation delay through the air delivery conduit.
  • In one form of the invention, the apparatus may be programmed as an asthma attack or asthma-related symptom detector to trigger treatment or to provide a warning of the occurrence of such an attack or such symptoms. In this embodiment, the microprocessor in the device reads the flow signal and determines on a breath-by-breath basis, an index of the roundness or alternatively flatness of the inspiratory portion of the flow time curve. The inspiratory portion of a normal breath waveform has a round shape. If the inspiratory portion of the waveform is flattened or shaped like a square-wave, then it is indicative of partial obstruction of the airway, for example, constriction or narrowing of the bronchus or other asthma-related narrowing of the airways of the lung. One form of flatness index is the RMS deviation of the inspiratory flow curve from a square wave of the same length and area. One form of roundness index is the RMS deviation from a sine wave of the same length and area. Alternatively, the inspiratory flow curve may be scaled to have unit length and area and compared to square and sine waves of unit dimensions. Examples of the formulae for calculating such indices are disclosed in U.S. Pat. No. 5,704,345 which is hereby incorporated by reference.
  • An inspiratory waveform which closely resembles a square wave will have a small RMS deviation from that waveform and hence have a small flatness index. Conversely, it will have a larger RMS deviation from the sine wave and have a larger roundness index. An inspiratory waveform which closely resembles a sine wave will have a small RMS deviation from that waveform and hence a small roundness index. Conversely, it will have a larger RMS deviation from a square wave and have a larger flatness index. Hence the device provides an alarm and logs the information when the roundness and flatness indices indicate the presence of partial obstruction when compared with predetermined thresholds. In this way the device can determine physiologic changes in the user's breathing patterns and indicate the onset of changes consistent with the onset or occurrence of an asthma attack.
  • In another form of the invention, the apparatus monitors the shape of the expiratory portion of the flow time curve. Abnormally shaped expiratory flow time curves are taken to be indications of the presence of a partial obstruction and the device responds by issuing a warning, logging the event and indicating the possible need for therapy. For example, this may be accomplished by analyzing an expiratory waveform to determine a flatness or roundness index.
  • In an embodiment of the invention, the delivery of therapeutic agents or treatments is monitored and recorded together with time and date stamp and other clinically relevant data including user blood oxygen concentration, environmental conditions such as current allergen load and ambient humidity. This data is then processed and made available, say to the clinician, for review. Reported statistics may include frequency and time distribution of airway events (such as deviation from the desired inspiratory or expiratory flow curve) and therapy doses. This data is used for the management of the patient in accessing their response to therapies and as an aid in determining future therapeutic agent dosing. Should there be identified a set of parameters which correlate with an airway event then the device may be programmed to respond by delivery of a predetermined therapeutic response (say by delivery of a therapeutic agent in a predetermined titration regime or ventilatory assistance) and thereby manage the patient's condition in a timely manner. If desired the device can be programmed to act in a proactive manner by recognizing the onset of conditions that have previously resulted in an airway event and deliver the therapeutic response to stabilize the patient prior to the patient having an airway event that warrants a more significant therapeutic response.
  • The effectiveness of a therapeutics response may be studied by programming the device to only provide a therapeutic response to an identified set of conditions (e.g. patient physiological state or atmospheric conditions or both) on some occasions and not on others. By examination of the monitored data it is possible to determine the effectiveness of the therapeutic response.
  • In a further embodiment a data management system will build and regularly update templates of patient responses to conditions and therapeutic responses in order to characterize patient responses and thereby provide patient specific data to an expert system decision tree. The decision tree may be used to determine future therapy strategies.
  • To broaden the system's diagnostic usefulness there may be provided the capacity to eliminate the filtered air reaching the patient so that unfiltered air reaches the patient. This capacity allows for the ability to identify correlations between environmental contaminates and airway events and therapeutic responses.
  • In another form of the invention, the apparatus is provided with an attachment for spirometry in the mask. The nose is blocked and the patient is instructed to take a deep breath and blow into the tubing in accordance with known techniques for measuring respiratory function. The device measures the flow and pressure and logs the peak flow and the total volume exhaled during the first 1 second of exhalation. The data from these measurements are available for both the patient and physician.
  • In one embodiment, the apparatus automatically detects the efficiency or status of the air cleaning device. For example, the controller is configured to monitor the impedance of an air filter by monitoring the power required to deliver a certain pressure and flow or some other measurable function of the blower such as its velocity or r.p.m. As the filter becomes blocked its impedance increases. When the filter impedance has reached a predetermined threshold, a warning is given as an alarm or message display to say that the filter should be replaced. In addition, the apparatus monitors the number of hours of use of the device since some filters ought to be replaced after a fixed number of hours of use. Suitable techniques and algorithms for such monitoring are described in international patent application No. PCT/AU99/0972 (also bearing international publication No. WO00/27457).
  • In another form of the invention, the apparatus delivers a higher pressure of air to the patient during the inspiratory portion of the patient's breathing cycle. In one form, the higher inspiratory pressure is less than 10 cm H2O. When the apparatus is delivering a therapeutic drug, for example by pumping the drug at pressure from a reservoir, the pressure of drug delivery is controlled to be higher than the mask pressure. Hence when the device delivers a higher mask pressure during the inspiratory portion of the patient's breathing cycle, the apparatus automatically increases the pressure of the drug delivery to be higher than the mask pressure by a predetermined offset.
  • Although the invention has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the application of the principles of the invention. Thus it is to be understood that numerous modifications may be made in the illustrative embodiments of the invention and other arrangements may be devised without departing from the spirit and scope of the invention

Claims (27)

1. An apparatus for the delivery of treatment for a patient with asthma, particularly during sleep, comprising:
a blower to generate a flow of breathable gas under pressure, with an inlet for receiving breathable gas to said blower,
a patient interface to provide said flow of breathable gas to the respiratory system of a patient,
a conduit between said interface and said blower to lead said flow of breathable gas to said interface,
a flow meter to generate a flow signal representative of flow to the patient,
a controller to control said blower's generation of said flow of breathable gas based in part on said flow signal, and
a cleaning device to clean said breathable gas to substantially prevent allergen particulates from reaching the patient.
2. The apparatus of claim 1 wherein said cleaning device is a filter.
3. The apparatus of claim 2 wherein said filter is a high efficiency particulate arresting filter.
4. The apparatus of claim 3 wherein said filter includes activated carbon.
5. The apparatus of claim 2 wherein said patient interface is a porous mask to insure CO2 washout at low pressures that covers the patient's nose openings and has a sealing membrane thickness in the range of 0.1 mm to 0.3 mm.
6. The apparatus of claim 5 wherein said controller controls said blower so as to vary said flow of breathable gas in response to the patient's respiration to maintain a relatively constant pressure at the patient interface.
7. The apparatus of claim 5 wherein said filter is replaceable and wherein said controller is adapted to monitor said blower to assess the filter's condition and to generate a warning when the assessment indicates that said filter should be changed.
8. The apparatus of claim 7 wherein said controller detects the number of hours of use of said blower.
9. The apparatus of claim 7 wherein said controller detects the impedance of said filter to assess the filter's condition as a function of signals from said flow meter.
10. The apparatus of claim 9 wherein said impedance is determined by the controller from the power of said blower in relation to pressure and flow from the blower.
11. The apparatus of claim 10 where said warning is an alarm.
12. The apparatus of claim 7 wherein said controller is configured to control said blower to generate a range of pressure from 1.75 to 2.5 cm H2O at the mask.
13. The apparatus of claim 2 wherein said controller includes a processor programmed with instructions for controlling an analysis of data from said flow signal to detect a symptom of asthma.
14. The apparatus of claim 13 wherein said analysis of data is a determination of a flow pattern including the steps of:
calculating a shape index from said data; and
comparing said index to a predetermined threshold.
15. The apparatus of claim 14 wherein said shape index is an indicator of the flatness of an inspiratory portion of patient flow.
16. The apparatus of claim 14 wherein said shape index is an indicator of the roundness of an inspiratory portion of patient flow.
17. The apparatus of claim 14 wherein said shape index is an indicator from an expiratory portion of patient flow.
18. The apparatus of claim 1 further comprising a controlled means for delivering a therapeutic substance to supplement said flow of breathable gas to the patient.
19. The apparatus of claim 18 wherein said controller controls said means for delivering the therapeutic substance to limit delivery of the substance during the patient's inspiratory cycle.
20. The apparatus of claim 19 wherein said therapeutic substance is a broncho-dilator.
21. The apparatus of claim 20 wherein said controlled means for delivering a therapeutic substance administers said therapeutic substance at said patient interface.
22. The apparatus of claim 13 further comprising a controlled means for delivering a therapeutic substance to supplement said flow of breathable gas to the patient.
23. The apparatus of claim 22 wherein said controller is further programmed with instructions for controlling a delivery of the therapeutic substance by said controlled means in response to a detection of a symptom of asthma.
24. The apparatus of claim 23 wherein said therapeutic substance is a broncho-dilator.
25. The apparatus of claim 23 wherein said therapeutic substance is a gas.
26. The apparatus of claim 25 wherein said gas is oxygen.
27-60. (canceled)
US13/030,488 2001-02-16 2011-02-18 Methods and apparatus for supplying clean breathable gas Abandoned US20110162644A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/030,488 US20110162644A1 (en) 2001-02-16 2011-02-18 Methods and apparatus for supplying clean breathable gas

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR3154 2001-02-16
AUPR3154A AUPR315401A0 (en) 2001-02-16 2001-02-16 An apparatus for supplying clean breathable gas
PCT/AU2002/000161 WO2002066105A1 (en) 2001-02-16 2002-02-15 Methods and apparatus for supplying clean breathable gas
US46760104A 2004-01-22 2004-01-22
US13/030,488 US20110162644A1 (en) 2001-02-16 2011-02-18 Methods and apparatus for supplying clean breathable gas

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/AU2002/000161 Continuation WO2002066105A1 (en) 2001-02-16 2002-02-15 Methods and apparatus for supplying clean breathable gas
US46760104A Continuation 2001-02-16 2004-01-22

Publications (1)

Publication Number Publication Date
US20110162644A1 true US20110162644A1 (en) 2011-07-07

Family

ID=3827173

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/467,601 Active 2030-03-18 US8622057B2 (en) 2001-02-16 2002-02-15 Methods and apparatus for supplying clean breathable gas
US13/030,488 Abandoned US20110162644A1 (en) 2001-02-16 2011-02-18 Methods and apparatus for supplying clean breathable gas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/467,601 Active 2030-03-18 US8622057B2 (en) 2001-02-16 2002-02-15 Methods and apparatus for supplying clean breathable gas

Country Status (4)

Country Link
US (2) US8622057B2 (en)
EP (1) EP1385566A4 (en)
AU (1) AUPR315401A0 (en)
WO (1) WO2002066105A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180028846A1 (en) * 2016-07-28 2018-02-01 Design West Technologies, Inc. Breath Responsive Powered Air Purifying Respirator
US10053949B2 (en) 2012-03-15 2018-08-21 Magnum Oil Tools International Ltd Cement retainer and squeeze technique
USD948027S1 (en) 2019-09-10 2022-04-05 Fisher & Paykel Healthcare Limited Connector for a breathing conduit
US11446462B2 (en) 2015-03-31 2022-09-20 Fisher & Paykel Healthcare Limited Apparatus for use in a respiratory support system
USD974551S1 (en) 2020-12-09 2023-01-03 Fisher & Paykel Healthcare Limited Connector assembly and connector
US11690995B2 (en) 2011-08-10 2023-07-04 Fisher & Paykel Healthcare Limited Conduit connector for a patient breathing device
USD995758S1 (en) 2021-06-11 2023-08-15 Fisher & Paykel Healthcare Limited Tube assembly and connector
USD1006981S1 (en) 2019-09-06 2023-12-05 Fisher & Paykel Healthcare Limited Breathing conduit

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2574232T3 (en) 1999-08-05 2016-06-16 Resmed R&D Germany Gmbh Device for supplying respiratory air, humidification device, respiratory gas tube and connection device for it
AU2003903138A0 (en) * 2003-06-20 2003-07-03 Resmed Limited Method and apparatus for improving the comfort of cpap
DE202004021794U1 (en) 2003-06-20 2011-02-10 ResMed Ltd., Bella Vista Breathing apparatus with humidifier
AU2003903139A0 (en) 2003-06-20 2003-07-03 Resmed Limited Breathable gas apparatus with humidifier
EA010994B1 (en) * 2004-03-29 2008-12-30 КейСиАй ЛАЙСЕНЗИНГ, ИНК. Method and apparatus foe controlling at least one ventilation parameter of an artificial ventilator for ventilating the lungs of a patient in accordance with a plurality of lung positions
GB0412482D0 (en) * 2004-06-03 2004-07-07 Intersurgical Ltd Improvements relating to medical respiratory apparatus
US7195014B2 (en) * 2005-03-22 2007-03-27 Hoffman Laboratories, Llc Portable continuous positive airway pressure system
ITRM20050217A1 (en) * 2005-05-06 2006-11-07 Ginevri S R L PROCEDURE FOR NASAL VENTILATION AND ITS APPARATUS, IN PARTICULAR FOR NEONATAL FLOW-SYNCHRONIZED ASSISTED VENTILATION.
GB2452442B (en) * 2005-06-02 2009-07-08 Intersurgical Ag Improvements relating to Medical Respiratory Apparatus
US20070163588A1 (en) * 2005-11-08 2007-07-19 Jack Hebrank Respirators for Delivering Clean Air to an Individual User
WO2007053878A1 (en) * 2005-11-08 2007-05-18 Resmed Ltd Nasal assembly
US20080142010A1 (en) * 2006-09-20 2008-06-19 Next Safety, Inc. Systems, methods, and apparatuses for pulmonary drug delivery
GB0620535D0 (en) * 2006-10-17 2006-11-22 Air Safety Ltd Filter
WO2008058330A1 (en) 2006-11-14 2008-05-22 Resmed Ltd Frame and vent assembly for mask assembly
AU2008218120A1 (en) 2007-02-23 2008-08-28 Augustine Biomedical And Design, Llc Personal air filtration device
US20080307970A1 (en) 2007-02-23 2008-12-18 Augustine Biomedical And Design, Llc Neck-worn air filtration device
WO2008116165A2 (en) * 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
US20090223368A1 (en) * 2008-03-07 2009-09-10 Augustine Biomedical And Design, Llc Distal hose end filter
BRPI0906296A2 (en) * 2008-04-04 2015-07-07 3M Innovative Properties Co Air filtration device.
US8414671B2 (en) * 2008-10-06 2013-04-09 Augustine Biomedical And Design, Llc Personal air filtration device for use with bedding structure
CN103961775B (en) 2009-06-02 2017-04-12 瑞思迈有限公司 Unobtrusive nasal mask
CN105674439B (en) * 2009-11-04 2019-02-19 野崎淳夫 Aircleaning facility and the health diagnosis system for having used it
US20110126828A1 (en) * 2009-11-27 2011-06-02 Fu-Chi Wu Personal air purifier
WO2012050521A1 (en) * 2010-10-14 2012-04-19 Ngee Ann Polytechnic A breathing apparatus
CN105999504B (en) 2011-04-15 2019-09-27 费雪派克医疗保健有限公司 Interface including wrap-up bridge of the nose part
US10603456B2 (en) 2011-04-15 2020-03-31 Fisher & Paykel Healthcare Limited Interface comprising a nasal sealing portion
DE102011120217A1 (en) * 2011-12-05 2013-06-06 Dräger Medical GmbH Nose adapter system for CPAP ventilation
BR112014017924A8 (en) 2012-01-20 2017-07-11 Huntleigh Technology Ltd THERMAL SUPPORT AND CONTROL SYSTEM
NZ716599A (en) * 2012-04-30 2017-08-25 Resmed Ltd Method and apparatus for oral flow therapy
EP4279106A3 (en) 2012-09-04 2024-01-17 Fisher & Paykel Healthcare Limited Valsalva mask
CN105555345B (en) 2013-08-05 2018-03-30 费雪派克医疗保健有限公司 Combination for the interface used in positive pressure respiration treatment is provided and its with face shield assembly
CN103736187B (en) * 2013-12-13 2015-11-11 科迈(常州)电子有限公司 A kind of two persistent levels positive pressure respirator
USD739007S1 (en) 2014-03-14 2015-09-15 3M Innovative Properties Company Powered air purifying respirator unit control panel
DE102014005544A1 (en) * 2014-04-16 2015-10-22 Sata Gmbh & Co. Kg Respiratory protection device
JP6684727B2 (en) 2014-06-17 2020-04-22 フィッシャー アンド ペイケル ヘルスケア リミテッド Patient interface
GB2585605B (en) 2014-08-25 2021-07-07 Fisher & Paykel Healthcare Ltd Respiratory mask and related portions, components or sub-assemblies
AU2015347003C1 (en) 2014-11-14 2021-04-01 Fisher & Paykel Healthcare Limited Patient interface
US10905836B2 (en) 2015-04-02 2021-02-02 Hill-Rom Services Pte. Ltd. Manifold for respiratory device
EP3344318B1 (en) 2015-09-04 2021-11-03 Fisher & Paykel Healthcare Limited Patient interfaces
US10773044B2 (en) * 2015-09-23 2020-09-15 ResMed Pty Ltd Vent adaptor for a respiratory therapy system
CA3036634A1 (en) 2016-10-05 2018-04-12 Fisher & Paykel Healthcare Limited Patient interfaces
US11197970B2 (en) * 2016-10-11 2021-12-14 Fisher & Paykel Healthcare Limited Integrated sensor assembly of a respiratory therapy system
EP3541458B1 (en) * 2016-11-18 2021-11-03 ResMed Pty Ltd Apparatus for ventilatory treatment of respiratory disorders
CN106765727B (en) * 2017-01-09 2019-08-16 西人马(厦门)科技有限公司 Air purifier and particle concentration detection method
USD823455S1 (en) 2017-02-23 2018-07-17 Fisher & Paykel Healthcare Limited Cushion assembly for breathing mask assembly
USD823454S1 (en) 2017-02-23 2018-07-17 Fisher & Paykel Healthcare Limited Cushion assembly for breathing mask assembly
USD824020S1 (en) 2017-02-23 2018-07-24 Fisher & Paykel Healthcare Limited Cushion assembly for breathing mask assembly
USD884153S1 (en) 2018-04-04 2020-05-12 Fisher & Paykel Healthcare Limited Frame for a mask assembly
CN109057864B (en) * 2018-08-21 2020-10-16 苏州南师大科技园投资管理有限公司 Local gas alarm device based on internet
CN113226384A (en) * 2018-12-28 2021-08-06 埃戴拉公司 Dynamic mask for diffusion of purified air
KR102458616B1 (en) * 2020-06-24 2022-10-28 엘지전자 주식회사 Mask apparatus and controlling method thereof
CN116648295A (en) * 2020-12-04 2023-08-25 瑞思迈私人有限公司 Air filtration device and system for providing patient information

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258710A (en) * 1978-08-16 1981-03-31 Reber Fred L Mask-type respirator
US4629482A (en) * 1985-08-05 1986-12-16 Enviracaire Corporation HEPA room air purifier
US4685944A (en) * 1982-06-09 1987-08-11 Flanders Filters, Inc. High efficiency particulate air filter
US4765326A (en) * 1987-04-20 1988-08-23 Minnesota Mining And Manufacturing Company Low-flow alarm system for powdered air-purifying respirator
US4971052A (en) * 1988-07-26 1990-11-20 Racal Safety Limited Breathing apparatus
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
US5413097A (en) * 1992-01-25 1995-05-09 Dragerwerk Ag Fan-supported gas mask and breathing equipment with adjustable fan output
US5485827A (en) * 1990-12-05 1996-01-23 The General Hospital Corporation Methods and devices for treating plumonary vasoconstriction and asthma
US5540225A (en) * 1991-11-14 1996-07-30 Alliance Pharmaceutical Corp. Method and apparatus for partial liquid ventilation or fluorocarbons
US5577496A (en) * 1993-04-14 1996-11-26 Mine Safety Appliances Company Respiratory protective apparatus
US5645054A (en) * 1992-06-01 1997-07-08 Sleepnet Corp. Device and method for the treatment of sleep apnea syndrome
US5704345A (en) * 1993-11-05 1998-01-06 Resmed Limited Detection of apnea and obstruction of the airway in the respiratory system
DE19626924A1 (en) * 1996-07-04 1998-01-08 Epazon B V Breathing gas supply device
US5776213A (en) * 1994-10-14 1998-07-07 Monsanto Company Respiratory filter and sampling device
US5896857A (en) * 1996-12-20 1999-04-27 Resmed Limited Valve for use in a gas delivery system
US5950621A (en) * 1995-03-23 1999-09-14 Safety Equipment Sweden Ab Powered air-purifying respirator management system
US6029660A (en) * 1996-12-12 2000-02-29 Resmed Limited Substance delivery apparatus
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US6286508B1 (en) * 1991-11-14 2001-09-11 University Technologies International, Inc. Auto CPAP system profile information
US6289974B1 (en) * 1997-07-11 2001-09-18 Elastek, Inc. Integrated heat recovery ventilator HEPA filter using a HEPA filter material regenerative heat exchanger
US6349724B1 (en) * 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
US6561190B1 (en) * 1997-02-10 2003-05-13 Resmed Limited Mask and a vent assembly therefor
US6581594B1 (en) * 2000-05-15 2003-06-24 Resmed Limited Respiratory mask having gas washout vent and gas washout vent for respiratory mask
US7827981B2 (en) * 2003-01-29 2010-11-09 Vapotherm, Inc. Method for reducing the work of breathing

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38772A (en) * 1863-06-02 Improvement in breech-loading fsre-arms
US719858A (en) * 1901-08-15 1903-02-03 Oscar Pike Jr Meat-tenderer.
GB8608113D0 (en) 1986-04-03 1986-05-08 Racal Safety Ltd Breathing apparatus
GB2215615B (en) 1988-03-21 1991-12-18 Sabre Safety Ltd Breathing apparatus
DE9317450U1 (en) 1993-11-15 1994-06-09 Metrax Gmbh Ventilator
GB2300814B (en) * 1995-05-18 1999-08-04 Omeresan Dediare Portable personal air conditioning device
IL114964A (en) * 1995-08-16 2000-10-31 Versamed Medical Systems Ltd Computer controlled portable ventilator
AUPO163896A0 (en) 1996-08-14 1996-09-05 Resmed Limited Determination of respiratory airflow
AUPO247496A0 (en) * 1996-09-23 1996-10-17 Resmed Limited Assisted ventilation to match patient respiratory need
DE69836532D1 (en) 1997-02-18 2007-01-11 David J Korman AIR FILTERING AND AIR SUPPLY SYSTEMS FOR PEOPLE
US6026660A (en) * 1997-05-13 2000-02-22 Gramercy Enterprises Corp. Jewelry setting
WO1999064747A1 (en) 1998-06-11 1999-12-16 Resmed Limited A housing for a centrifugal impeller
AUPP693398A0 (en) * 1998-11-05 1998-12-03 Resmed Limited Fault diagnosis in CPAP and NIPPV devices
AUPP794598A0 (en) 1998-12-24 1999-01-28 Resmed Limited An anti-asphyxia valve
US7168429B2 (en) * 2001-10-12 2007-01-30 Ric Investments, Llc Auto-titration pressure support system and method of using same

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258710A (en) * 1978-08-16 1981-03-31 Reber Fred L Mask-type respirator
US4685944A (en) * 1982-06-09 1987-08-11 Flanders Filters, Inc. High efficiency particulate air filter
US4629482A (en) * 1985-08-05 1986-12-16 Enviracaire Corporation HEPA room air purifier
US4765326A (en) * 1987-04-20 1988-08-23 Minnesota Mining And Manufacturing Company Low-flow alarm system for powdered air-purifying respirator
US4971052A (en) * 1988-07-26 1990-11-20 Racal Safety Limited Breathing apparatus
US5485827A (en) * 1990-12-05 1996-01-23 The General Hospital Corporation Methods and devices for treating plumonary vasoconstriction and asthma
US5873359A (en) * 1990-12-05 1999-02-23 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5540225A (en) * 1991-11-14 1996-07-30 Alliance Pharmaceutical Corp. Method and apparatus for partial liquid ventilation or fluorocarbons
US6286508B1 (en) * 1991-11-14 2001-09-11 University Technologies International, Inc. Auto CPAP system profile information
US5413097A (en) * 1992-01-25 1995-05-09 Dragerwerk Ag Fan-supported gas mask and breathing equipment with adjustable fan output
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
US5645054A (en) * 1992-06-01 1997-07-08 Sleepnet Corp. Device and method for the treatment of sleep apnea syndrome
US5577496A (en) * 1993-04-14 1996-11-26 Mine Safety Appliances Company Respiratory protective apparatus
US5704345A (en) * 1993-11-05 1998-01-06 Resmed Limited Detection of apnea and obstruction of the airway in the respiratory system
US5776213A (en) * 1994-10-14 1998-07-07 Monsanto Company Respiratory filter and sampling device
US5950621A (en) * 1995-03-23 1999-09-14 Safety Equipment Sweden Ab Powered air-purifying respirator management system
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
DE19626924A1 (en) * 1996-07-04 1998-01-08 Epazon B V Breathing gas supply device
US6029660A (en) * 1996-12-12 2000-02-29 Resmed Limited Substance delivery apparatus
US6189532B1 (en) * 1996-12-16 2001-02-20 Resmed Limited Valve for use in a gas delivery system
US5896857A (en) * 1996-12-20 1999-04-27 Resmed Limited Valve for use in a gas delivery system
US6561190B1 (en) * 1997-02-10 2003-05-13 Resmed Limited Mask and a vent assembly therefor
US6289974B1 (en) * 1997-07-11 2001-09-18 Elastek, Inc. Integrated heat recovery ventilator HEPA filter using a HEPA filter material regenerative heat exchanger
US6581594B1 (en) * 2000-05-15 2003-06-24 Resmed Limited Respiratory mask having gas washout vent and gas washout vent for respiratory mask
US6349724B1 (en) * 2000-07-05 2002-02-26 Compumedics Sleep Pty. Ltd. Dual-pressure blower for positive air pressure device
US7827981B2 (en) * 2003-01-29 2010-11-09 Vapotherm, Inc. Method for reducing the work of breathing

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690995B2 (en) 2011-08-10 2023-07-04 Fisher & Paykel Healthcare Limited Conduit connector for a patient breathing device
US10053949B2 (en) 2012-03-15 2018-08-21 Magnum Oil Tools International Ltd Cement retainer and squeeze technique
US11446462B2 (en) 2015-03-31 2022-09-20 Fisher & Paykel Healthcare Limited Apparatus for use in a respiratory support system
US20180028846A1 (en) * 2016-07-28 2018-02-01 Design West Technologies, Inc. Breath Responsive Powered Air Purifying Respirator
US10888721B2 (en) * 2016-07-28 2021-01-12 Design West Technologies, Inc. Breath responsive powered air purifying respirator
USD1006981S1 (en) 2019-09-06 2023-12-05 Fisher & Paykel Healthcare Limited Breathing conduit
USD948027S1 (en) 2019-09-10 2022-04-05 Fisher & Paykel Healthcare Limited Connector for a breathing conduit
USD983353S1 (en) 2019-09-10 2023-04-11 Fisher & Paykel Healthcare Limited Connector for a breathing conduit
USD974551S1 (en) 2020-12-09 2023-01-03 Fisher & Paykel Healthcare Limited Connector assembly and connector
USD995758S1 (en) 2021-06-11 2023-08-15 Fisher & Paykel Healthcare Limited Tube assembly and connector

Also Published As

Publication number Publication date
AUPR315401A0 (en) 2001-03-15
EP1385566A1 (en) 2004-02-04
US20040112381A1 (en) 2004-06-17
WO2002066105A1 (en) 2002-08-29
US8622057B2 (en) 2014-01-07
EP1385566A4 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
US8622057B2 (en) Methods and apparatus for supplying clean breathable gas
EP1778326B1 (en) Energy trigger
US7793660B2 (en) Method of treating obstructive sleep apnea
JP4083154B2 (en) Duration of inspiration in CPAP or assisted breathing procedures
US5551419A (en) Control for CPAP apparatus
US8366631B2 (en) System and method for detecting respiratory events
JP5715066B2 (en) System and method for treating lung disease using positive airway pressure support
ES2235277T3 (en) INSPIRATION PRESSURE SYSTEM FOR RESPIRATORY ROADS.
JP5689092B2 (en) Apnea / hypopnea determination during CPAP treatment
JP2019048054A (en) System and method for determining sleep stage, and readable medium
US20080092894A1 (en) System and method for controlling respiratory therapy based on detected respiratory events
NZ734910A (en) Respiratory therapy apparatus and method
US20110201957A1 (en) Carbon dioxide monitoring system
JP2019514557A (en) System for determining airway patency
CA2589922A1 (en) Respiratory devices and methods of use
US8875705B2 (en) Protocol and methods for pulsating drug delivery
US20230078997A1 (en) Methods and apparatus for treatment of respiratory disorders
CN108366756B (en) Apparatus, system and method for determining breathing characteristics of a subject based on breathing gas
CN108066865B (en) Medical device and method for determining an operating situation in a medical device
CN108290019B (en) Method and apparatus for treating ataxic breathing
US20220347415A1 (en) Patient interface and component detection, monitoring and replacement
WO2001091841A1 (en) Method and apparatus for leak detection, by analysing humidity of ventilation gas with optical means
JP2001314507A (en) Medical oxygen concentrator
ES2599856T3 (en) Positive proportional airway pressure device without sensor
US20210299379A1 (en) Artificial respiration

Legal Events

Date Code Title Description
AS Assignment

Owner name: RESMED LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UJHAZY, ANTHONY JOHN;WRIGHT, JONATHAN CALDWELL;DREW, JOANNE ELIZABETH;AND OTHERS;SIGNING DATES FROM 20040114 TO 20040119;REEL/FRAME:025833/0364

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION